Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

This study is designed to evaluate whether epigenetic markers in overweight men with type 1 diabetes (T1D) or type 2 diabetes (T2D) can be improved with a 3 month lifestyle intervention or program focused in glycemic intervention.

Study Overview

• Status: Recruiting
• Conditions: Overweight; Type 2 Diabetes Mellitus; Type 1 Diabetes Mellitus
• Intervention / Treatment: Other: Lifestyle Intervention; Other: No Intervention

Detailed Description

Parental history of diabetes confers substantial individual risk for development of obesity and diabetes. Obesity risk can be transmitted across generations, from parents or grandparents to children. Genomic variation explains only a portion of this risk. Epigenetic modulation through DNA methylation, histone modification, or by noncoding RNAs, provide mechanisms to regulate gene activity independent of DNA sequence by determining which genes are turned on or off in response to environment or disease. Epigenetic changes can be stable over the lifespan providing a mechanism through which environmental exposures may impart long-term effects on gene expression and phenotypic outcome.

The maternal intrauterine environment is now well recognized to modify obesity and T2D disease risk of offspring. Fetuses carried by women who are obese, have diabetes, or suffer from suboptimal nutrition are at increased risk of insulin resistance, obesity, T2D, and cardiovascular disease risk as adults. Studies in rodents also show that the health, metabolism, and prior environmental exposures of the male can also influence health of his offspring. Existing data provide powerful support for the hypothesis that current glucose levels and overall metabolic health of males can alter epigenetic marks in sperm and suggest a novel modifiable mechanism of transmission. However, much less is known about how human sperm epigenetic patterns change with nutritional and metabolic health, and whether these may ultimately impart differences in health of future generations. Thus, we are studying the impact of both type 1 and type 2 diabetes, and elevations in glucose common to both conditions, on human reproductive health and the sperm epigenome.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Mary E Patti, MD; Phone Number: 6173092635; Email: mary.elizabeth.patti@joslin.harvard.edu
• Study Contact Backup: Name: Elvira Isganaitis, MD; Email: elvira.isganaitis@joslin.harvard.edu

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Recruiting
      • Joslin Diabetes Center
      • Contact: Elvira Isganaitis, MD; Email: elvira.isganaitis@joslin.harvard.edu
      • Sub-Investigator: Elvira Isganaitis, MD
      • Contact: Mary E Patti, MD; Phone Number: 617-309-2635; Email: mary.elizabeth.patti@joslin.harvard.edu
      • Principal Investigator: Mary E. Patti, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male, age 18-65 years
• Willing and able to provide informed consent and follow all study procedures, including providing sperm specimens 3 months apart.
• Type 1 or type 2 diabetes diagnosis confirmed by an endocrinologist (for participants in the diabetes groups)
• HbA1c > 7% (for participants in the diabetes groups)
• Overweight (BMI > 25 kg/m2) (for all groups, to ensure groups are similar)

Exclusion Criteria:

• Chronic kidney disease stage 4 or 5 (including end-stage renal disease);
• Hepatic disease, including serum alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL; or serum bilirubin > 2.0;
• Severe diabetic retinopathy;
• Congestive heart failure, New York Heart Association (NYHA) class II, III or IV;
• History of myocardial infarction, unstable angina or revascularization within the past 6 months;
• Active genitourinary infection;
• Testicular volume <12 mL (assessed using Prader orchidometer);
• Hypogonadism, defined as total testosterone <250 ng/dl;
• Hyperprolactinemia, defined as prolactin >18 ng/ml;
• Hyperestrogenism, defined as estradiol >42 pg/ml;
• Cryptorchidism;
• Cigarette smoking;
• Active alcohol abuse or substance abuse;
• Cancer (except localized non-melanoma skin cancers) or use of chemotherapy agents within 5 years;
• Use of nitrates or guanylate cyclase stimulators;
• Use of steroid hormones (including testosterone), other than inhalers for reactive airway disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lifestyle Intervention; 20 overweight men with T1D or T2D will undergo an intensive 3 month lifestyle intervention program aimed at improving metabolic health, glycemic control, and body weight.	Other: Lifestyle Intervention; Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
Active Comparator: No-Intervention Controls; 10 overweight men with T1D or T2D will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.	Other: No Intervention; Participants will not undergo an intervention.
Active Comparator: Healthy Controls; 10 healthy men will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.	Other: No Intervention; Participants will not undergo an intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Spermatozoa concentration	Sperm will be assessed for concentration, reported as total yield (millions per ml)	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sperm DNA methylation, reported as genomic location of regions with methylation altered in response to intervention	We will utilize purified DNA (1.5 μg), sheared by sonication to obtain 200-700 bp fragments for subsequent library preparation for methylation-dependent immunoprecipitation and sequencing. Differentially methylated regions (DMR) are identified using methylated DNA immunoprecipitation coupled with next-generation sequencing (MEDIPS). DNA methylation is assessed using sliding windows (500 bp size, 200 bp shift). Regions with read ratios >1.5 or <0.67 and binomial p<0.0001 in independent biologically replicated comparisons are designated as DMR.	1 year
RNA Sequencing	RNA will be isolated from sperm samples and subjected to RNA sequencing to analyze the content of both of large messenger ribonucleic acid (mRNA)/noncoding RNA and small RNAs. Data will be analyzed to identify those species altered in response to intervention.	1 year

Collaborators and Investigators

• Sponsor: Joslin Diabetes Center

Publications and helpful links

General Publications

• Sales VM, Ferguson-Smith AC, Patti ME. Epigenetic Mechanisms of Transmission of Metabolic Disease across Generations. Cell Metab. 2017 Mar 7;25(3):559-571. doi: 10.1016/j.cmet.2017.02.016.

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2018
• Primary Completion (Estimated): July 1, 2024
• Study Completion (Estimated): July 1, 2024

Study Registration Dates

• First Submitted: October 11, 2018
• First Submitted That Met QC Criteria: February 28, 2019
• First Posted (Actual): March 4, 2019

Study Record Updates

• Last Update Posted (Actual): August 3, 2023
• Last Update Submitted That Met QC Criteria: August 2, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Overnutrition; Nutrition Disorders; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1; Overweight
• Other Study ID Numbers: 2015-40

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No